These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18266023)

  • 1. A vitamin K epoxide reductase complex subunit 1 mutation in an Irish patient with warfarin resistance.
    Ainle FN; Mumford A; Tallon E; McCarthy D; Murphy K
    Ir J Med Sci; 2008 Jun; 177(2):159-61. PubMed ID: 18266023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1.
    Harrington DJ; Underwood S; Morse C; Shearer MJ; Tuddenham EG; Mumford AD
    Thromb Haemost; 2005 Jan; 93(1):23-6. PubMed ID: 15630486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists.
    Stepien E; Branicka A; Ciesla-Dul M; Undas A
    J Appl Genet; 2009; 50(4):399-403. PubMed ID: 19875892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].
    Loriot MA; Beaune P
    Rev Med Interne; 2006 Dec; 27(12):979-82. PubMed ID: 17070618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance.
    Bodin L; Horellou MH; Flaujac C; Loriot MA; Samama MM
    J Thromb Haemost; 2005 Jul; 3(7):1533-5. PubMed ID: 15978113
    [No Abstract]   [Full Text] [Related]  

  • 6. Novel VKORC1 mutations associated with warfarin sensitivity.
    Baniasadi S; Beizaee S; Kazemi B; Behzadnia N; Shafaghi B; Bandehpour M; Fahimi F
    Cardiovasc Ther; 2011 Aug; 29(4):e1-5. PubMed ID: 20579077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
    Scott SA; Edelmann L; Kornreich R; Desnick RJ
    Am J Hum Genet; 2008 Feb; 82(2):495-500. PubMed ID: 18252229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consequences of the Y139F Vkorc1 mutation on resistance to AVKs: in-vivo investigation in a 7th generation of congenic Y139F strain of rats.
    Grandemange A; Kohn MH; Lasseur R; Longin-Sauvageon C; Berny P; Benoit E
    Pharmacogenet Genomics; 2009 Oct; 19(10):742-50. PubMed ID: 19752778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.
    Rost S; Fregin A; Ivaskevicius V; Conzelmann E; Hörtnagel K; Pelz HJ; Lappegard K; Seifried E; Scharrer I; Tuddenham EG; Müller CR; Strom TM; Oldenburg J
    Nature; 2004 Feb; 427(6974):537-41. PubMed ID: 14765194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Warfarin resistance in a French strain of rats.
    Lasseur R; Longin-Sauvageon C; Videmann B; Billeret M; Berny P; Benoit E
    J Biochem Mol Toxicol; 2005; 19(6):379-85. PubMed ID: 16421894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin.
    Rost S; Fregin A; Hünerberg M; Bevans CG; Müller CR; Oldenburg J
    Thromb Haemost; 2005 Oct; 94(4):780-6. PubMed ID: 16270630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records.
    Osman A; Enström C; Arbring K; Söderkvist P; Lindahl TL
    J Thromb Haemost; 2006 Aug; 4(8):1723-9. PubMed ID: 16879214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin K epoxide reductase complex subunit 1 (VKORC1 ) polymorphism influences the anticoagulation response subsequent to vitamin K intake: a pilot study.
    Sconce EA; Avery PJ; Wynne HA; Kamali F
    J Thromb Haemost; 2008 Jul; 6(7):1226-8. PubMed ID: 18466315
    [No Abstract]   [Full Text] [Related]  

  • 14. Pesticide resistance in wild mammals--mechanisms of anticoagulant resistance in wild rodents.
    Ishizuka M; Tanikawa T; Tanaka KD; Heewon M; Okajima F; Sakamoto KQ; Fujita S
    J Toxicol Sci; 2008 Aug; 33(3):283-91. PubMed ID: 18670159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The genetic basis of resistance to anticoagulants in rodents.
    Pelz HJ; Rost S; Hünerberg M; Fregin A; Heiberg AC; Baert K; MacNicoll AD; Prescott CV; Walker AS; Oldenburg J; Müller CR
    Genetics; 2005 Aug; 170(4):1839-47. PubMed ID: 15879509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients.
    Michaud V; Vanier MC; Brouillette D; Roy D; Verret L; Noel N; Taillon I; O'Hara G; Gossard D; Champagne M; Goodman K; Renaud Y; Brown A; Phillips M; Ajami AM; Turgeon J
    Clin Pharmacol Ther; 2008 May; 83(5):740-8. PubMed ID: 18030307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.
    Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY
    Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new cell culture-based assay quantifies vitamin K 2,3-epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol-driven VKOR assay.
    Fregin A; Czogalla KJ; Gansler J; Rost S; Taverna M; Watzka M; Bevans CG; Müller CR; Oldenburg J
    J Thromb Haemost; 2013 May; 11(5):872-80. PubMed ID: 23452238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of the coumarin anticoagulant targeted vitamin K epoxide reduction system. Study of kinetic parameters in susceptible and resistant mice (Mus musculus domesticus).
    Lasseur R; Grandemange A; Longin-Sauvageon C; Berny P; Benoit E
    J Biochem Mol Toxicol; 2006; 20(5):221-9. PubMed ID: 17009238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.